Press Releases

Syntarga Announces Additional Antibody-Drug Conjugate Collaborations

May 31, 2010
Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements c...
Read more

Syntarga Announces Two Antibody-Drug Conjugate Collaborations with Top-tier Biopharmaceutical Companies

March 03, 2010
Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These latest agreements, adding t...
Read more

Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund

January 29, 2010
Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fu...
Read more

Merus receives EuroTransBio Grant

December 15, 2009
Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the developme...
Read more

ISA Pharmaceuticals announces NEJM publication on VIN phase II data

November 11, 2009
New England Journal of Medicine Publishes a highly Successful Clinical Study by Leiden University Medical Center and ISA Pharmaceuticals B.V. with a therapeutic HPV vaccine in patients with premalignant vulv...
Read more

Orca Therapeutics receives VCN License

September 30, 2009
ORCA Therapeutics BV a biopharmaceutical company in the field of virotherapy, announces that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic a...
Read more

Syntarga Announces Patent Grant for SpaceLink Technology for Antibody-Drug Conjugation

July 16, 2009
Syntarga B.V. announces that as of today patents have been granted for its proprietary SpaceLink Technology in Europe (EP 1370298 B1), the United States (US 7,223,837), India, China, New Zealand and Australi...
Read more

ISA Pharmaceuticals names Nigel Crockett Business Development director

July 09, 2009
ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...
Read more

InteRNA Technologies joins TI Pharma by signing new project to develop novel anti-angiogenic miRNA-based therapeutics

July 06, 2009
Three new small and medium enterprises (SMEs), Syncom, Synvolux Therapeutics and InteRNA Technologies, have joined the public-private partnership TI Pharma by participating in two new projects. The two proje...
Read more

Kees Melief, CSO of ISA Pharmaceuticals, receives prestigious Coley Award

June 05, 2009
FOR IMMEDIATE RELEASE Scientific & Corporate Leaders in Immunology, Tumor Immunology to be Honored at Cancer Research Institute 23rd Annual Awards Dinner 2009 Grace and Coley Award Winners Announced May 29,...
Read more

InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

April 22, 2009
Bilthoven and Nijmegen (the Netherlands) - InteRNA Technologies B.V. and Radboud University Nijmegen Medical Centre have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for p...
Read more

ISA Pharmaceuticals appoints Gerard Platenburg as CEO

April 21, 2009
ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...
Read more

Syntarga Demonstrates In Vivo Proof of Concept for its Antibody-Drug Conjugate Technology

January 08, 2009
Syntarga B.V. announced today that it has demonstrated strong and broad In Vivo Proof of Concept for Antibody-Drug Conjugates (ADCs) incorporating the Company's payload technology. The proprietary platform c...
Read more
Previous 1 2 3 4 5 6 7

Home > Press Releases > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds